Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL

By afschroeder • June 26, 2026

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand RG, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine JP, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik SA, Mathews J, Shaughnessy PJ, Mountjoy L, Dykes KC, Logan AC, Schwartz MS, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg RT, Tracy SI, Yalniz FF, Yaghmour G, Pullarkat VA, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I. Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL. Blood Adv. 2026 Jun 25:bloodadvances.2026020707. doi: 10.1182/bloodadvances.2026020707. Epub ahead of print. PMID: 42349018.

Tags: Hematology/Oncology, Publications

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Semenova G, Frank SB, Dumpit R, Han W, Coleman I, Gulati R, Dirican CD, Arman T, Maruwan J, Morrissey C, Haffner MC, Nelson PS, Lee[...]

FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin[...]

The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy

Markosian C, Schiller GJ. The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy. Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03023-z. Epub[...]